

Haematologica  
HAEMATOL/2020/249276  
Version 3

SMAD1 promoter hypermethylation and lack of SMAD1 expression in Hodgkin lymphoma: a potential target for hypomethylating drug therapy

Magdalena M. Gerlach, Anna Stelling-Germani, Cheuk Ting Wu, Sebastian Newrzela, Claudia Döring, Visar Vela, Anne Müller, Sylvia Hartmann, and Alexandar Tzankov

Disclosures: none

Contributions: Magdalena M. Gerlach wrote the manuscript and evaluated the histology and immunohistochemical stains Anna Stelling-Germani supervised SMAD1 promoter methylation assessment, performed cell line viability experiments, corrected the manuscript and wrote the legend to Figure 2 Cheuk Ting Wu assessed SMAD1 promoter methylation Sebastian Newrzela provided gene expression data of Hodgkin lymphoma cell lines Claudia Döring provided and analyzed gene expression data of Hodgkin lymphoma cell lines Visar Vela enriched Hodgkin and Reed-Sternberg cells from archival clinical samples and isolated DNA from them Anne Müller supervised SMAD1 promoter methylation assessment Sylvia Hartmann provided cell lines Alexandar Tzankov designed the study, supervised histopathologic assessment, performed statistics, analyzed gene expression data of Hodgkin lymphoma cell lines, partially wrote and completely edited the manuscript